Posted September 21, 2017
San Francisco, CA (August 21st, 2017) – TMS Health Solutions announced today that they are have reviewed and tabulated all evaluations from 2017 Advanced Hands-On TMS Symposium and begun planning the upcoming year. “We were thrilled by feedback on the four-day event and have kicked off the discussion for 2018,” said Karl Lanocha, Director of Education for TMS Health Solutions and Course Chair for the Advanced Hands-on Transcranial Magnetic Stimulation (TMS) Symposium. “We were pleased that attendees found the symposium meaningful, from commenting on the hands-on time across manufacturers to noting the informing and engaging didactic lectures.”
Feedback from attendees on hands-on device training included comments such as “…both lectures and equipment demos were valuable,” nodding towards training on all four major manufacturer’s machines. Machine instruction was given directly by a few of the faculty, all renown experts in TMS. Dr. Nolan Williams, an Instructor of Psychiatry at Stanford, provided training on the Brainsway device. Dr. Ian Cook, Director of the UCLA Depression Research and Clinic Program at the Semel Institute, gave training on the Magstim device. Dr. Mark Demitrak, who has written extensively on the neuroendocrinology of mood disorders, Dr. Paul Croarkin, on the faculty of the Mayo Clinic, and Dr. Phil Janicak, Adjunct Professor at Northwestern University Feinberg School of Medicine, each led different times of training on Neurostar. Dr. Rich Bermudes, Chief Medical Director at TMS Health Solutions, and Dr. Lanocha provided training for the MagVenture device.
The didactic lectures were rated to be highly valuable by attendees. A number of participants commented on the importance of “.. learning about the pivotal studies…” of TMS through the didactic lectures. Each of the ten faculty members prepared a lecture on an array of TMS-related subjects. Dr. Mark George of the Medical University of South Carolina provided an in-depth discussion on the role of TMS in therapeutic neuromodulation in psychiatry, which was highly praised by attendees. “It was useful to know what TMS responders do not gain tolerance to effects,” said one attendee. “(This will help me) better incorporate measurement outcomes in using TMS,” commented one attendee in regards to Associate Professor at UT Southwestern and Adjunct Professor at Duke Dr. Shawn McClintock’s presentation on “Setting up a TMS Practice.” Dr. Jonathan Downer’s presentation on “More Remission More Often: Matching the Stimulation Target to the Patient” included fodder for potential applications of TMS, or, as one attendee commented, “(The presentation helped me) better understand cortical circuits and the future of TMS.”
Given that TMS is one of the fastest growing therapies in Psychiatry, the Symposium’s four days were powerful days of learning, training, and discussion, as indicated by course feedback and attendee comments. “We’re already looking at dates for 2018,” promised Dr. Rich Bermudes.
About TMS Therapy:
Cleared by the FDA in 2008, TMS is a drug-free, non-invasive therapy for patients who suffer from treatment-resistant depression. It is administered in a physician’s office in an outpatient setting. By using a MRI-strength magnetic field to stimulate the prefrontal cortex of the brain, the core symptoms of major depression can be relieved. Unlike antidepressants or Electroconvulsive Therapy (ECT), patients undergoing TMS therapy experience minimal side effects.
About TMS Health Education:
Headquartered in San Francisco, TMS Health Education is an education company that provides CME credits and continuing medical education and brings together the nation’s leading academics and clinical practitioners to present the most current and relevant information on the treatment of clinical depression illness through Transcranial Magnetic Stimulation (TMS) therapy. TMS Health Education is led by Dr. Richard Bermudes and Dr. Karl Lanocha, two of the nation’s leading experts on TMS therapy.